Psychedelic Research Bulletin: May 2021

Psychedelic Bulletin: MindMed CEO Steps Down; Atai Targets $2.3bn Valuation

Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

PTSF63 – The Media and Legalization, Joints for Jabs, and 40,000...

Atai Targets $2.3bn Valuation in Nasdaq IPO

atai Life Sciences Announces Launch of Initial Public Offering

LSD and the Anarchic Brain

Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit...

Red Light Holland Closes Acquisition of 80% of Happy Caps Mushroom...

PharmaTher Provides Research and Development Update and Milestones for 2021

Load more